Citations

Clear

79 citation(s) found for "Janus, Jeffrey".

Multidisciplinary Management of Tracheal Perforation: A Case of Successful Reconstruction and Stenting
Valdes‐Camacho, Sofia , Murillo‐Torres, Regina M. , Rojas-Zapata, Tatiana A. , Lee‐Mateus, Alejandra Yu , Gutierrez‐Gallegos, Paola , Valencia, Bastien A. , Anderson, Elise, Robertson, Kelly S , Fernández-Bussy, Sebastián , Janus, Jeffrey R. , Yu Lee-Mateus, Alejandra , Valencia‐Sanchez, Bastien A. , Abia-Trujillo, David , Abia‐Trujillo, David

Mayo Clinic

Respirology Case Reports | July 8, 2026 | Volume: 14 | Issue: 7 | Pages: No page available

10.1002/rcr2.70661 | PMID 42416892 Get It

ABSTRACT Airway perforation is a potentially lethal complication from tracheal or mediastinal malignancies that require complex management. Advanced thyroid cancer is known to have high morbidity, and patients with tracheal metastatic lesions are vulnerable to injury. Therapeutic management typically comprises a combination of surgical and nonoperative treatment modalities, whose adverse effects can lead to significant airway injury. We present the case of a 67‐year‐old man with papillary thyroid carcinoma who developed a tracheocutaneous fistula following proton beam therapy and chemotherapy for metastatic disease. Airway repair and recanalization were successfully achieved through a combined surgical and bronchoscopic approach.
De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer
Hidalgo, C. , Bogan, Aaron, Rourk, Katelyn S. , Baratz, Hannah , Eyassu, Daniel G. , Price, Katharine A., Moore, Eric J. , Patel, Samir H., Hinni, Michael L., Neben-Wittich, M.A. , Garces, Yolanda I. , McGee, L.A. , Wilson, Jessica, Rwigema, Jean-Claude M., Chintakuntlawar, Ashish V., Mohammadi, Homan , Price, Daniel L., Janus, Jeffrey R. , Garcia, Joaquin J., Foote, Robert L., Tasche, Kendall K. , Ma, Daniel J., Hidalgo, Cecelia M, Baratz, Hannah Q , Neben-Wittich, Michelle A, Lester, Scott C. , Holtzman, Adam L. , Rwigema, Jean‐Claude M. , Chintakuntlawar, Ashish V. , Price, Daniel L. , García, Joaquín J., Foote, Robert L. , Abel, Kathryn M. Van , Yin, Linda X. , Routman, David M.

Mayo Clinic

JAMA Network Open | May 18, 2026 | Volume: 9 | Issue: 5 | Pages: e2612837

10.1001/jamanetworkopen.2026.12837 | PMID 42149594 Get It

Importance Standard adjuvant therapy for human papillomavirus–associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is radiation therapy 60 Gy with or without cisplatin delivered in 30 fractions during 6 weeks. A phase 3 randomized clinical trial demonstrated decreased toxic effects and improved patient-reported outcomes with de-escalated adjuvant radiation therapy (DART) compared with standard therapy; however, outcomes for patients treated in the clinical practice setting following trial adoption remain unknown. Objective To compare characteristics and oncologic outcomes of patients treated with DART during clinical trials (on study) and in clinical practice settings (off study) and report progression-free survival (PFS) by risk category. Design, Setting, and Participants This retrospective cohort study included patients treated with DART in the MC1273 and MC1675 trials and in clinical practice after study completion at a multisite tertiary care center. Patients with surgically resectable HPV-OPSCC who underwent margin-negative resection between August 20, 2013, and March 21, 2023, and were treated with DART were included in the analysis. Those with prior head and neck cancer, pT0 or pT4 disease, unknown HPV status, metastatic disease at presentation, synchronous primary tumors, induction chemotherapy, or treatment at an outside institution were excluded. Data were analyzed from July 1, 2024, to July 18, 2025. Interventions DART consisting of 30 to 36 Gy in 1.5- to 1.8-Gy fractions twice daily with docetaxel 15 mg/m 2 on days 1 and 8. Main Outcomes and Measures Progression-free survival as measured via Kaplan-Meier analysis. Results A total of 282 patients were included in the analysis: 176 (62.4%) in the on-study group and 106 (37.6%) in the off-study group (252 [89.4%] male; mean [SD] age, 59.1 [9.3] years). Both groups were predominantly male (157 [89.2%] and 95 [89.6%], respectively) and consisted mostly of never smokers (118 [67.0%] and 62 [58.5%], respectively). Pathologic features were similar between groups except for nodal stage (pN1: 155 [88.1%] on study vs 102 [96.2%] off study; pN2: 21 [11.9%] on study vs 4 [3.8%] off study; P = .02). The median follow-up times were 5.2 years (95% CI, 5.2-5.8 years) in the on-study group and 2.2 years (95% CI, 1.9-2.4 years) in the off-study group. Two-year PFS was similar (93% [95% CI, 88%-97%] on study vs 93% [95% CI, 88%-99%] off study). For patients with pN1 and no extranodal extension (ENE), 2- and 5-year PFS were 97% (95% CI, 93%-100%) and 96% (95% CI, 92%-100%), respectively. Patients with pN1 and ENE had a 2- and 5-year PFS of 93% (95% CI, 89%-98%) and 87% (95% CI, 81%-94%), respectively. Conclusions and Relevance In this retrospective cohort study of patients receiving DART on and off study, oncologic outcomes were similar between the 2 groups. Fewer patients with pN2 received DART off study, given the interim results of MC1675. Patients with pN1 and no ENE treated with DART had excellent 2- and 5-year PFS, supporting DART as a compelling treatment option in well-selected patients. An additional study that is currently underway will evaluate biomarker risk-stratified treatment of patients with pN1 and ENE receiving DART.
Primary hyperparathyroidism due to dual parathyroid adenomas: one orthotopic, one intrathymic in ectopic cervical thymus
Iglesias, Migdalia , Lewis, Jason, Janus, Jeffrey, Abate, Ejigayehu G., Chindris, Ana‐Maria , Abate, Ejigayehu, Chindris, Ana-Maria

Mayo Clinic

JCEM Case Reports | February 20, 2026 | Volume: 4 | Issue: 5 | Pages: No page available

10.1210/jcemcr/luag061 | PMID 42027586 Get It

Abstract Primary hyperparathyroidism is most commonly caused by a single parathyroid adenoma. Multiple and ectopic adenomas are less common and can present diagnostic challenges. We present the case of a 57-year-old woman with hypercalcemia, hypercalciuria, and inappropriately normal parathyroid hormone (PTH) levels. Sestamibi scan did not demonstrate abnormal uptake; however, contrast-enhanced 4-dimensional computed tomography imaging reported 2 candidate lesions described as tubular shaped structures located posterior to the inferior pole of each thyroid lobe. Surgical exploration was performed and the surgical pathology reported hypercellular parathyroid tissue resected from the left inferior thyroid bed and benign thymic tissue with embedded hypercellular parathyroid tissue resected from the right inferior thyroid bed. Postoperative calcium levels normalized, and the patient remained eucalcemic at 1-year follow-up. This case underscores the importance of embryologic understanding and thorough surgical exploration in patients with biochemically confirmed primary hyperparathyroidism and inconclusive imaging.
Immunotherapy and Radiation for Clinical Perineural Invasion in Cutaneous Squamous Cell Carcinoma
Morecroft, Renée , Phillipps, Jordan , Gou, Lang, Bhatt, Alok A. , Kim, Sungjune , Mohammadi, Homan , Dronca, Roxana , Chen, Ruqin, Zhao, Yujie , Kang, Hye Seon , Li, Shenduo , Janus, Jeffrey R. , Pirgousis, Phillip , Patel, Samip , Okuyemi, Oluwafunmilola T., Singer, Elisha M., Tolaymat, Leila , Wysong, Ashley , Degesys, Catherine A. , Holtzman, Adam L. , Morecroft, Renee A , Phillipps, Jordan S, Dronca, Roxana S., Zhao, Yujie , Pirgousis, Phillip , Patel, Samip N , Wysong, Ashley , Barbosa, Naiara, Holtzman, Adam , Bhatt, Alok A , Gou, Lang, Doonan, Bently P. , Barbosa, Naiara S.

Mayo Clinic

Cancers | December 8, 2025 | Volume: 17 | Issue: 24 | Pages: 3921

10.3390/cancers17243921 | PMID 41463172 Get It

Localized cutaneous squamous cell carcinoma (cSCC) has a favorable prognosis, unlike advanced disease, especially with clinical perineural invasion (PNI), which poses substantial management challenges due to aggressivity and higher recurrence, metastasis, and mortality risks. PNI, a high-risk staging feature, has worse outcomes, particularly when clinically evident rather than incidental. Clinical PNI (cPNI) is evident by clinical symptoms (such as pain, paresthesia, or motor deficits) or radiologic findings, whereas incidental PNI (iPNI) is identified only histologically without associated symptoms or radiologic evidence. PNI remains a novel area with varying practice patterns across institutions. Improving risk stratification and tailoring multidisciplinary approaches are critical for optimizing outcomes. Our review outlines clinical practice patterns at our institution, providing insights into managing cSCC with PNI, focusing on diagnosis, imaging, staging, and emerging immunotherapies. A structured search was conducted using the terms “perineural invasion,” “cutaneous squamous cell carcinoma,” and “immunotherapy.” cPNI has a poor prognosis and requires nuanced clinical decision-making. Surgery and radiation remain central to management. Adjuvant therapy offers substantial survival benefit in cSCC with PNI, with improved disease-free and overall survival compared with surgery alone, supporting its use in appropriately selected high-risk patients. Traditional systemic therapies, including cisplatin and cetuximab, remain foundational but have shown only moderate response rates and limited durability in advanced or neurotropic cSCC. In contrast, immunotherapy—now preferred for advanced or unresectable cases—has transformed management, with programmed cell death protein-1 (PD-1) inhibitors showing promising results (up to 69% response rate) and disease stabilization. Neoadjuvant immunotherapy may enable tumor downstaging, improve radiation planning, and reduce surgical morbidity. Imaging for squamous cell carcinoma (SCC) with PNI aids staging and surveillance, but symptoms remain key for detecting recurrence. Our multidisciplinary approach emphasizes personalized care. Larger trials are needed to define the optimal role and sequencing of immunotherapy in this high-risk patient population.
Novel Assessment of Advanced Practice Provider‐Led Head and Neck Cancer Survivorship Clinic: Quality‐of‐Care Metric Analysis and HOUSES Index Application
Wert, K. , May, Byron C. , Janus, Jeffrey R. , Patel, Samip , Pirgousis, Phillip , Zhao, Yujie , Li, Shenduo , Price, Katharine A., McGee, L.A. , Daniel, J. , Kim, Sungjune , Mohammadi, Homan , Wert, Katey , McGee, Lisa A , Ma, Daniel , Routman, David M , Wi, Chung-Ii , Kim, Sungjune , Holtzman, Adam , Patel, Samip N , Janus, Jeffrey R , Routman, David M. , Wi, Chung‐Il , Holtzman, Adam L.

Mayo Clinic

Head & Neck | October 3, 2025 | Volume: 48 | Issue: 2 | Pages: 528-534

10.1002/hed.70062 | PMID 41041809 Get It

ABSTRACT Background As head and neck cancer survival rates improve, there is growing demand for quality survivorship care and tools to predict patient adherence; this study aims to evaluate an advanced practice provider ( APP )‐led survivorship clinic and assess these key metrics. Methods We performed a retrospective review of 213 head and neck cancer patients treated with curative radiation therapy between 2016 and 2023, to assess follow‐up adherence in an advanced practice provider–led survivorship clinic. Results With a median follow‐up of 2.4 years, follow‐up care metrics identified high completion percentages (> 90%) for lung cancer screening, smoking cessation, thyroid screening, dental evaluation, xerostomia, dysphagia, and dysgeusia. The HOUsing ‐based SocioEconomic Status ( HOUSES ) index at diagnosis showed a significant adherence difference (median percentile, 78% vs. 55%, adherent vs. nonadherent; p = 0.03). Conclusions High adherence rates with guideline‐defined care metrics are achievable in an advanced practice provider‐led head and neck cancer survivorship clinic. The HOUSES index may assist in predicting nonadherence; however, further studies are needed.
Individualized Surgical Management for Thyroglossal Duct Cyst‐Papillary Thyroid Carcinoma: A Case Series
Dahiya, Rockey , Weiss, Natalie , May, Ryan, Chindris, Ana‐Maria , Janus, Jeffrey R. , Pirgousis, Phillip , May, Ryan, Chindris, Ana-Maria , Reynolds, Jordan

Mayo Clinic

The Laryngoscope | July 12, 2025 | Volume: 135 | Issue: 10 | Pages: 3951-3956

10.1002/lary.32403 | PMID 40650637 Get It

ABSTRACTObjectivesThyroglossal duct cyst (TGDC) associated carcinoma is rare, accounting for less than 2% of TGDC cases. The majority of cases are classified as papillary thyroid carcinoma (PTC). Standard treatment for TGDC‐PTC involves a Sistrunk procedure and prophylactic total thyroidectomy (TT). However, the necessity of these extensive surgical interventions remains debated. This report aims to explore whether individualized surgical approaches may reduce morbidity while maintaining favorable oncological outcomes.MethodsRetrospective case series of three patients with TGDC‐PTC.ResultsThe age range at presentation for our patients with TGDC‐PTC was 26 to 50. Case 1 involved a 38‐year‐old patient with a cystic mass near the hyoid bone and submental lymphadenopathy who underwent cyst excision with level Ia lymph node clearance. Case 2 is of a 50‐year‐old patient with a history of TGDC‐PTC who presented with a recurrent neck mass 9 years after the initial surgery and underwent a revision Sistrunk procedure. Case 3 presents a 26‐year‐old patient with a large TGDC and a benign thyroid nodule who underwent a Sistrunk procedure. All three patients had PTC confirmed by final pathology. All had no evidence of recurrent disease at follow‐up evaluations ranging from 1 to 12 years.ConclusionThis case series demonstrates the feasibility and safety of individualized surgical management for TGDC‐PTC. Risk stratification allowed for tailored interventions and avoided overly aggressive approaches. Further studies are needed to establish definitive guidelines for managing TGDC‐PTC, particularly in low‐risk patients.Level of Evidence4.
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma
Abel, Kathryn M. Van , Price, Katharine A., Moore, Eric J. , Patel, Samir H. , Hinni, Michael L., Fruth, Briant, Foster, Nathan R. , Neben-Wittich, M.A. , Garces, Yolanda I. , McGee, L.A. , Gamez, Mauricio E. , Rwigema, Jean‐Claude M. , Janus, Jeffrey R. , Kasperbauer, Jan L. , García, Joaquín J., Foote, Robert L. , Daniel, Jeannie, Neben-Wittich, Michelle, McGee, Lisa A, Lester, Scott C. , Holtzman, Adam L. , Van Abel, Kathryn M , Routman, David M. , Yin, Linda X. , Price, Daniel L. , Chintakuntlawar, Ashish V. , Ma, Daniel J.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 22, 2025 | Volume: 151 | Issue: 7 | Pages: 665

10.1001/jamaoto.2025.0903 | PMID 40402484 Get It

ImportanceThe De-escalated Adjuvant Radiation Therapy (DART) phase 3 randomized clinical trial (RCT) showed that in patients with human papillomavirus (HPV)−associated oropharyngeal squamous cell carcinoma, postoperative minimal residual disease (MRD), detected through circulating tumor HPV DNA (ctHPVDNA), was associated with a higher risk of disease progression. When considered along with pathologic factors, postoperative ctHPVDNA assessment may improve patient selection for adjuvant treatment de-escalation; however, more data are needed to demonstrate how it may be used in personalizing treatment intensity.ObjectiveTo determine the association of postoperative MRD status with progression-free survival (PFS) after surgery for HPV-associated oropharyngeal squamous cell carcinoma.Design, Setting, and ParticipantsThis was a secondary analysis of the DART RCT, which was conducted from October 2016 to August 2020 in multiple sites in the US. Participants from the de-escalated adjuvant radiation therapy group and the standard of care group with available blood specimen data were included. Reports from 3-month posttreatment surveillance visits were used to assess associations and outcomes. Data analyses were performed from March 2023 to March of 2025.InterventionsThe DART group received 30 to 36 Gy of radiation therapy in 1.5 to 1.8 Gy twice daily, plus docetaxel, 15 mg/m2, on days 1 and 8. The standard of care group received 60 Gy with or without weekly cisplatin, 40 mg/m2.Main Outcome and MeasurePFS.ResultsThe analysis included 140 patients (mean [SD] age, 59.1 [8.4] years; 12 [8.6%] females and 128 [91.4%] males; 97 [69.3%] with no smoking history); characteristics were similar to the overall DART RCT population. Of these, 17 patients (12.1%) had postoperative MRD (13 of 96 [13.5%] receiving DART and 4 of 44 [9.1%] receiving standard of care). For all patients, postoperative MRD positivity was strongly associated with worsened PFS at 24 months (MRD positivity, 69.5%; MRD negativity, 95.9%; hazard ratio [HR], 0.19; 95% CI, 0.06-0.59). MRD positivity was associated with PFS when evaluating only those patients in the DART group, where 24-month PFS was 68.4% compared to 92.6% for MRD-negative patients (HR, 0.28; 95% CI, 0.08-0.93). Three months after completion of all treatment, 8 of 117 patients (6.8%) had detectable ctHPVDNA, whereas 109 of 117 (93.2%) did not, and detection was highly associated with PFS (HR, 20.48; 95% CI, 6.91-60.67).Conclusions and RelevanceThis secondary analysis of the DART RCT found that patients with detectable ctHPVDNA after surgery had a higher risk of disease progression. When added to the pathologic factors considered, ctHPVDNA assessment may improve selection of patients for treatment de-escalation. In addition, the 3-month posttreatment time point, early in surveillance, may identify a sizable portion of patients with progression and may guide intervention and surveillance after surgery for HPV-associated oropharyngeal squamous cell carcinoma.Trial RegistrationClinicalTrials.gov Identifier: NCT02908477
Current Diagnostics and management of submandibular space schwannoma: a systematic review
Vasudevan, Srivatsa Surya , Caballero, Anyull D. Bohorquez, Kandrikar, Tiba Yamin , Janus, Jeffrey R. , Candelo, Estephanía , Bohorquez Caballero, Anyull D, Green, Katerina J. , Janus, Jeffrey R , Caballero, Anyull D. Bohorquez, Green, Katerina

Mayo Clinic

Acta Oto-Laryngologica | April 23, 2025 | Volume: 145 | Issue: 6 | Pages: 545-553

10.1080/00016489.2025.2486611 | PMID 40262932 Get It

Diagnostic, survival, and tumor control outcomes of parapharyngeal space liposarcoma: a systematic review
Vasudevan, Srivatsa Surya , Kandrikar, Tiba Yamin , Janus, Jeffrey R. , Candelo, Estephanía

Mayo Clinic

Acta Oto-Laryngologica | February 21, 2025 | Volume: 145 | Issue: 4 | Pages: 348-354

10.1080/00016489.2025.2462688 | PMID 39982322 Get It

Carbon Radiotherapy for Rare Tumors: Electronic Consent and Follow-up
Galatas, Aimée , Mohammadi, Homan , Janus, Jeffrey R. , Zhao, Yujie , Donaldson, Angela M. , Olomu, Osarenoma , Holtzman, Adam L. , Patel, Samip , Almeida, João Paulo , Liu, Emily L. , Haydu, Lauren E. , Hoppe, Bradford S.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 7, 2025 | Volume: 86 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1803628 Get It